HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals (NASDAQ:INO) in a report published on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Maxim Group restated a buy rating and set a $8.00 target price on shares of Inovio Pharmaceuticals in a report on Thursday, August 16th. ValuEngine cut shares of Inovio Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 24th. BidaskClub upgraded shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 24th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, July 3rd. Finally, Stifel Nicolaus initiated coverage on shares of Inovio Pharmaceuticals in a report on Tuesday, October 2nd. They set a buy rating and a $8.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $10.75.

Inovio Pharmaceuticals stock opened at $5.29 on Tuesday. The company has a market capitalization of $508.72 million, a PE ratio of -4.85 and a beta of 1.74. Inovio Pharmaceuticals has a twelve month low of $3.64 and a twelve month high of $6.43.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.27. Inovio Pharmaceuticals had a negative net margin of 252.95% and a negative return on equity of 71.53%. The business had revenue of $24.45 million during the quarter, compared to analysts’ expectations of $2.13 million. Sell-side analysts expect that Inovio Pharmaceuticals will post -1.07 EPS for the current fiscal year.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 49,060 shares of the company’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $5.37, for a total transaction of $263,452.20. Following the sale, the chief executive officer now directly owns 2,357,554 shares of the company’s stock, valued at $12,660,064.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp raised its position in shares of Inovio Pharmaceuticals by 3.4% in the second quarter. Northern Trust Corp now owns 1,026,797 shares of the biopharmaceutical company’s stock valued at $4,026,000 after purchasing an additional 33,555 shares during the period. Bank of America Corp DE raised its position in shares of Inovio Pharmaceuticals by 36.6% in the second quarter. Bank of America Corp DE now owns 114,660 shares of the biopharmaceutical company’s stock valued at $449,000 after purchasing an additional 30,740 shares during the period. BlackRock Inc. raised its position in shares of Inovio Pharmaceuticals by 5.5% in the second quarter. BlackRock Inc. now owns 6,845,338 shares of the biopharmaceutical company’s stock valued at $26,834,000 after purchasing an additional 356,105 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Inovio Pharmaceuticals by 8.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 445,846 shares of the biopharmaceutical company’s stock valued at $1,748,000 after purchasing an additional 33,567 shares during the period. Finally, Levin Capital Strategies L.P. raised its position in shares of Inovio Pharmaceuticals by 80.5% in the second quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 16,500 shares during the period. 31.52% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Story: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.